表紙
市場調查報告書

焦點市場分析:良性前列腺肥大症(BPH)

Market Spotlight: Benign Prostatic Hyperplasia (BPH)

出版商 Datamonitor Healthcare 商品編碼 939990
出版日期 內容資訊 英文 32 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:良性前列腺肥大症(BPH) Market Spotlight: Benign Prostatic Hyperplasia (BPH)
出版日期: 2020年08月04日內容資訊: 英文 32 Pages
簡介

本報告提供全球良性前列腺肥大症(BPH)治療市場調查,彙整疾病的背景·概要,主要的治療方法,主要的開發平台藥物概要,主要的已上市藥物趨勢,授權·資產收購等企業間的主要交易趨勢,專利資訊,臨床試驗狀況等資料。

目錄

概要

重要點

疾病的背景

治療

  • 後續觀察
  • 藥理學性治療
  • 外科的治療

流行病學

成藥

開發平台藥物

最新案例和分析師的見解

  • BPH的複數藥(2019年6月25日)
  • BPH用OPK-88004(2019年1月31日)
  • BPH的複數設備(2018年11月20日)

成功的概率

許可證與資產買進交易

本源專利

商機

臨床試驗情勢

  • 各狀態贊助商
  • 不同階段贊助商

參考文獻

  • 處方箋資訊

附錄

目錄
Product Code: DMKC0184659

This Market Spotlight report covers the Benign Prostatic Hyperplasia market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 305.5 million prevalent cases of benign prostatic hyperplasia (BPH) among males aged 40 years and older worldwide, and forecasts that number to increase to 373.8 million prevalent cases by 2028.

Asia is estimated to have had the largest number of prevalent cases in 2019, and Oceania is estimated to have had the smallest number (188.5 million and 2.0 million cases, respectively).

Approved drugs in the BPH space target phosphodiesterase 5, steroid 5a-reductase, alpha 1 adrenergic receptor, and muscarinic acetylcholine receptor. All marketed drugs for BPH are administered via the oral route.

The largest proportion of industry-sponsored drugs in active clinical development for BPH are in Phase II, with one drug in Phase III.

Therapies in active clinical development for BPH focus on targets such as apoptosis, mitochondria, reactive oxygen species/free radicals, estrogen receptor beta, steroid 5a-reductase, and phosphodiesterase 5. These therapies are administered via the intratumoral, intravenous, and oral routes.

The overall likelihood of approval of a Phase I urology asset is 12.7%, and the average probability a drug advances from Phase III is 77.3%. Drugs, on average, take 9.0 years from Phase I to approval in the overall urology space.

The distribution of clinical trials across Phase I-IV indicates that just over half of trials for BPH have been in the early and midphases of development, with 54% of trials in Phase I-II, and 46% in Phase III-IV.

The US has a substantial lead in the number of BPH clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.

Clinical trial activity in the BPH space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for BPH, with 65 trials.

GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for BPH, followed by Astellas and Sanofi

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Watchful waiting
  • Pharmacological treatment
  • Surgical treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Multiple Drugs for BPH (June 25, 2019)
  • OPK-88004 for BPH (January 31, 2019)

KEY REGULATORY EVENTS

  • UK's NICE Recommends Boston Scientific's Rezum Steam Treatment For BPH

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of BPH, 2019-28
  • Figure 2: Overview of pipeline drugs for BPH in the US
  • Figure 3: Pipeline drugs for BPH, by company
  • Figure 4: Pipeline drugs for BPH, by drug type
  • Figure 5: Pipeline drugs for BPH, by classification
  • Figure 6: Probability of success in the BPH pipeline
  • Figure 7: Clinical trials in BPH
  • Figure 8: Top 10 drugs for clinical trials in BPH
  • Figure 9: Top 10 companies for clinical trials in BPH
  • Figure 10: Trial locations in BPH
  • Figure 11: BPH trials status
  • Figure 12: BPH trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of BPH, 2019-28
  • Table 2: Prevalence proportions of BPH, by age
  • Table 3: Marketed drugs for BPH
  • Table 4: Pipeline drugs for BPH in the US
  • Table 5: Multiple Drugs for BPH (June 25, 2019)
  • Table 6: OPK-88004 for BPH (January 31, 2019)
  • Table 7: Historical global sales, by drug ($m), 2015-19
  • Table 8: Forecasted global sales, by drug ($m), 2020-24